

Two-Lumen Hemodialysis Catheterization Product with ARROWg⁺ard® Antimicrobial Surface

Safety and Efficacy Considerations:

Do not use if package has been previously opened or damaged.

Warning: Read all package insert warnings, precautions, and instructions prior to use. Failure to do so may result in severe patient injury or death.

Do not alter the catheter, spring-wire guide, or any other kit/ set component during insertion, use, or removal.

Procedure must be performed by trained personnel well versed in anatomical landmarks, safe technique, and potential complications.



⚠ WARNING
DO NOT PLACE THE CATHETER INTO OR ALLOW IT TO REMAIN IN THE RIGHT ATRIUM OR RIGHT VENTRICLE. FAILURE TO FOLLOW THESE INSTRUCTIONS CAN RESULT IN SEVERE PATIENT INJURY OR DEATH.
READ INSTRUCTIONS

Cardiac Tamponade:

It has been documented by many authors that placement of indwelling catheters in the right atrium is a dangerous practice^{1,3,4,6,9,23,28} that may lead to cardiac perforation and tamponade.^{1,3,4,6,23,28} Although cardiac tamponade secondary to pericardial effusion is uncommon, there is a high mortality rate associated with it.³⁰ Practitioners placing central venous catheters must be aware of this potentially fatal complication before advancing the catheter too far relative to patient size. No particular route or catheter type is exempt from this potentially fatal complication.²⁸ The actual position of the tip of the indwelling catheter should be confirmed by x-ray after insertion.^{1,3,6,23,28,31} Central venous catheters should be placed in the superior vena cava^{1,3,4,6,9,23,34} above its junction with the right atrium and parallel to the vessel wall^{15,34} and its distal tip positioned at a level above either the azygos vein or the carina of the trachea, whichever is better visualized.

Central venous catheters should not be placed in the right atrium unless specifically required for special relatively short term procedures such as aspiration of air emboli during neurosurgery. Such procedures are, nevertheless, risk prone and should be closely monitored and controlled.

ARROWg⁺ard® Antimicrobial Surface: The Arrow® antimicrobial catheter consists of our standard polyurethane catheter with Blue FlexTip®, plus an exterior antimicrobial surface treatment of chlorhexidine acetate and silver sulfadiazine. Antimicrobial activity associated with ARROWg⁺ard Blue® catheters has been demonstrated in the following ways:

12-14 Fr. Catheter *In Vitro* Results:

- Antimicrobial activity associated with the ARROWg⁺ard Blue catheter has been established using a modified Kirby-Bauer assay (zones of inhibition) against the following organisms at 24 hours³⁹:

Acinetobacter baumannii
Candida albicans
Enterobacter aerogenes
Enterobacter cloacae
Enterococcus faecalis
Escherichia coli
Klebsiella pneumoniae
Pseudomonas aeruginosa
Methicillin-resistant Staphylococcus aureus (MRSA)
Staphylococcus epidermidis
Streptococcus pyogenes
Xanthomonas maltophilia

- Marked decreases in antimicrobial activity against all organisms are apparent at Day 7 of *in vitro* analysis.

Clinical Efficacy:

- Antimicrobial activity data associated with the ARROWg⁺ard Blue catheter have not been collected with the two-lumen hemodialysis catheter.
- A prospective, randomized, controlled clinical trial of 237 large-bore and central venous catheter insertions in 115 patients demonstrated that catheter-related bloodstream infections rates were 2.27/1000 catheter days for ARROWg⁺ard Blue catheters versus 3.95/1000 catheter days for nonimpregnated catheters (p=0.31).⁷
- A prospective, randomized, controlled clinical trial of 403 central venous catheter insertions in 158 adult patients in a medical-surgical ICU showed that ARROWg⁺ard Blue catheters were 50% less likely to be colonized at removal than the control catheters (13.5 compared to 24.1 colonized catheters per 100 catheters, p=0.005) and were 80% less likely to produce a bloodstream infection (1.0 compared to 4.7 infections per 100 catheters; 1.6 compared to 7.6 infections per 1000 catheter days, p=0.03).²²
- No adverse effects were seen from the antimicrobial catheter, and none of the isolates obtained from infected catheters in either group showed *in vitro* resistance to chlorhexidine or silver sulfadiazine.²²

- Complete data were obtained for 403 central venous catheters (195 control catheters and 208 antimicrobial catheters) in 158 patients. Control catheters removed from patients who were receiving systemic antibiotic therapy occasionally showed low-level surface activity that was unrelated to the length of time the catheter had been in place (mean zone of inhibition \pm SD, 1.7 ± 2.8 mm); in contrast, antimicrobial catheters uniformly showed residual surface activity (mean zone of inhibition, 5.4 ± 2.2 mm; $P < 0.002$), which declined after prolonged periods *in situ*. Antimicrobial activity was seen with antimicrobial catheters that had been in place for as long as 15 days.²²
- The ARROWg^{ard} Blue catheter has demonstrated a significant decrease in the rate of bacterial colonization along the catheter in limited animal studies.¹³
- An independent review of 11 randomized clinical trials on the ARROWg^{ard} Blue antimicrobial catheters (MEDLINE search from January 1966 to January 1998) concluded that central venous catheters impregnated with a combination of chlorhexidine acetate and silver sulfadiazine are effective in reducing the incidence of both catheter colonization and catheter-related bloodstream infections in patients at high risk for catheter-related infections.³⁷

If the total amount of silver sulfadiazine and chlorhexidine contained in the antimicrobial surface was released from the catheter as a single dose, the blood levels of silver, sulfadiazine, and chlorhexidine that would be found would be less than the blood levels found after clinical usage of these compounds in established safe dosages as administered via mucous membranes and skin.¹¹

The potential exposure of patients to the two agents, silver sulfadiazine and chlorhexidine, on the antimicrobial surface is significantly less than that encountered when these compounds are used on burn wounds, on cutaneous wounds, or as mucosal irrigants.¹¹

No adverse effects of a toxicologic nature have been associated with the clinical use of this antimicrobial surface in spite of the fact that catheters have been placed in patients sensitive to sulfonamides but who were unaware of their sensitivity.¹¹

Indications for Use:

The large-bore two-lumen catheter permits venous access to the central circulation for rapid fluid administration, temporary or acute hemodialysis, apheresis and hemofiltration. It may be inserted into the jugular, subclavian, or femoral veins.

The ARROWg^{ard} Blue antimicrobial surface catheter helps provide protection against catheter-related infections resulting from microorganisms migrating the subcutaneous tract along the exterior surface of the catheter when used for infusion. Clinical data have not been collected that demonstrate the use of the ARROWg^{ard} Blue antimicrobial surface in decreasing catheter-related infections in hemodialysis patients. The catheter is not intended to be used as a treatment for existing infections, nor is it indicated for long-term use.

Contraindications:

The Arrow large-bore two-lumen catheter is not designed for long-term hemodialysis or for use in patients with thrombosed vessels.

The ARROWg^{ard} Blue antimicrobial surface catheter is contraindicated for patients with known hypersensitivity to chlorhexidine, silver sulfadiazine, and/or sulfa drugs (refer to product instructions for references).

Special Patient Populations:

Controlled studies of the antimicrobial catheter have not been conducted in pregnant women,²⁴ and patients with known sulfonamide hypersensitivity, erythema multiforme, Stevens-Johnson syndrome,¹¹ and glucose-6-phosphate dehydrogenase deficiency. The benefits of the use of this catheter should be weighed against any possible risk.

Warnings and Precautions:*

1. **Warning: Sterile, Single use: Do not reuse, reprocess or resterilize. Reuse of device creates a potential risk of serious injury and/or infection which may lead to death.**
2. **Warning: Use of subclavian vein insertion site may be associated with subclavian stenosis.**^{40, 41, 42, 43}
3. **Warning: Do not place the catheter into or allow it to remain in the right atrium or right ventricle. Central vein catheters should be positioned so that the distal tip of the catheter is in the superior vena cava (SVC) above the junction of the SVC and the right atrium and lies parallel to the vessel wall. For femoral vein approach, the catheter should be advanced into the vessel so that the catheter tip lies parallel to the vessel wall and does not enter the right atrium.**
4. **Warning: Practitioners must be aware of complications associated with central vein catheters including cardiac tamponade secondary to vessel wall, atrial or ventricular perforation, pleural and mediastinal injuries, air embolism, catheter embolism, thoracic duct laceration, bacteremia, septicemia, thrombosis, inadvertent arterial puncture, nerve damage, hematoma, hemorrhage, dysrhythmias, brachial plexus injury, cardiac arrhythmia, exsanguination, hemothorax, luminal thrombosis, pneumothorax, subcutaneous hematoma, and retroperitoneal bleed.**
5. **Warning: Do not apply excessive force in removing guide wire or catheters. If withdrawal cannot be easily accomplished, a chest x-ray should be obtained and further consultation requested.**
6. **Warning: The practitioner must be aware of potential air embolism/hemorrhage associated with large-bore catheters. Do not leave open needles or catheters in central venous puncture sites. To lessen the risk of disconnects, only securely tightened Luer-Lock connections should be used with this device. It is recommended that the extension lines be kept clamped at all times when not in use because of the catheter's large lumens. Follow hospital protocol to guard against air embolism/hemorrhage for all catheter maintenance.**
7. **Warning: Passage of the guide wire into the right heart can cause dysrhythmias, right bundle branch block,¹⁰ and vessel wall, atrial or ventricular perforation.**
8. **Warning: Practitioners must be aware of the potential for entrapment of guide wire by any implanted device in the circulatory system (ie. vena cava filters, stents). Review patient's history before catheterization procedure to assess for possible implants. Care should be taken regarding the length of spring-wire guide inserted. It is recommended that if patient has a circulatory system implant, catheter procedure be done under direct visualization to minimize the risk of guidewire entrapment.**
9. **Warning: Due to the risk of exposure to HIV (Human Immunodeficiency Virus) or other blood borne pathogens, health care workers should routinely use universal blood and body-fluid precautions in the care of all patients.**

10. **Precaution:** Do not clamp the body of the large-bore catheter. Clamp only the extension lines and use only the clamps provided. Never use serrated forceps to clamp the extension lines.
11. **Precaution:** Indwelling catheters should be routinely inspected for desired flow rate, security of dressing, correct catheter position, and for secure Luer-Lock connection. Use centimeter markings to identify if the catheter position has changed.
12. **Precaution:** Only x-ray examination of the catheter placement can ensure that the catheter tip has not entered the heart or no longer lies parallel to the vessel wall. If catheter position has changed, immediately perform chest x-ray examination to confirm catheter tip position.
13. **Precaution:** For blood sampling, temporarily shut off remaining port(s) through which solutions are being infused.
14. **Precaution:** Alcohol and acetone can weaken the structure of polyurethane materials. Check ingredients of prep sprays and swabs for acetone and alcohol content. **Acetone:** Do not use acetone on catheter surface. Acetone may be applied to skin but must be allowed to dry completely prior to applying dressing. **Alcohol:** Do not use alcohol to soak catheter surface or to restore catheter patency. Care should be taken when instilling drugs containing high concentration of alcohol. Always allow alcohol to dry completely prior to applying dressing.
15. **Precaution:** Some disinfectants used at the catheter insertion site contain solvents, which can attack the catheter material. Assure insertion site is dry before dressing.
16. **Precaution:** Use of a syringe smaller than 10 mL to irrigate or de clot an occluded catheter may cause intraluminal leakage or catheter rupture.⁸
17. **Precaution:** When using a You-Bend™ catheter, the extension lines of You-Bend catheter are not to be re-formed on a continuous basis. Excessive re-forming of the extensions may lead to wire fatigue and breakage.

Kits/Sets may not contain all accessory components detailed in these instructions for use. Become familiar with instructions for individual component(s) before beginning the procedure.

A Suggested Procedure:

Use sterile technique.

1. **Precaution:** Place patient in slight Trendelenburg position as tolerated to reduce the risk of air embolism. If femoral approach is used, place patient in supine position.
2. Prep and drape puncture site as required.
3. Perform skin wheal with desired needle (25 Ga. or 22 Ga. needle). In kits where provided, a SharpsAway® disposal cup is used for the disposal of needles. Push needles into foam after use. Discard entire cup at completion of procedure. **Precaution:** Do not reuse needles after they have been placed into the disposal cup. Particulate matter may adhere to needle tip.
4. Prepare catheter for insertion by flushing each lumen and clamping or attaching injection caps to appropriate extension lines. Leave the distal extension line uncapped for guide wire passage. **Warning:** Do not cut catheter to alter length.

Arrow UserGard® Needle-Free Injection Hub (where provided)

Instructions for Use:

- Attach Luer end of UserGard hub to syringe.
- Prepare injection site with alcohol or betadine per standard hospital protocol.
- Remove red dust cap.
- Press UserGard hub onto injection site and twist to lock on pin (refer to Fig. 1).




Fig. 1

- Inject or withdraw fluid as required.
 - Disengage UserGard hub from injection site and discard. **Warning:** To minimize the risk of possible air embolism, do not leave UserGard hub connected to injection site. Single use only.
5. Insert introducer needle with attached Arrow® Raulerson Syringe (where provided) into vein and aspirate. (If larger introducer needle is used, vessel may be pre-located with 22 Ga. locator needle and syringe.) Remove locator needle. **Precaution:** The preferred insertion site for central venous catheters is the right internal jugular vein. Other options include the right external jugular vein, left internal and external jugular vein. Subclavian access should be used only when no other upper-extremity or chest-wall options are available.⁴⁴

Alternate Technique:

Catheter/needle may be used in the standard manner as alternative to introducer needle. If catheter/needle is used, Arrow Raulerson Syringe will function as a standard syringe, but will not pass spring-wire guide. If no free flow of venous blood is observed after needle is removed, attach syringe to the catheter and aspirate until good venous blood flow is established. **Precaution:** The color of blood aspirated is not always a reliable indicator of venous access.¹⁶ Do not reinsert needle into introducer catheter.

6. Because of the potential for inadvertent arterial placement, one of the following techniques should be utilized to verify venous access. Insert the fluid primed blunt tip transduction probe into the rear of the plunger and through the valves of the Arrow Raulerson Syringe. Observe for central venous placement via a wave form obtained by a calibrated pressure transducer. Remove transduction probe (refer to Fig. 2).




Fig. 2

Alternate Technique:

If hemodynamic monitoring equipment is not available to permit transducing a central venous wave form, check for pulsatile flow by either using the transduction probe to open the syringe valving system or by disconnecting the syringe from the needle. Pulsatile flow is usually an indicator of inadvertent arterial puncture.

- Using the two-piece Arrow Advancer, advance spring-wire guide through syringe into vein. **Warning: Aspiration with spring-wire guide in place will cause introduction of air into syringe. Precaution: To minimize the risk of leakage of blood from syringe cap do not reinfuse blood with spring-wire guide in place.**

Arrow Two-Piece Advancer Instructions (where provided):

- Using your thumb, straighten the “J” by retracting the spring-wire guide into the Advancer (refer to Figs. 3, 4).




Fig. 3




Fig. 4

When the tip is straightened, the spring-wire guide is ready for insertion. When using a marked guide wire, centimeter marks on guide wire are referenced from “J” end. One band indicates 10 cm, two bands 20 cm, and three bands 30 cm.

Introducing the Spring-Wire Guide:

- Place the tip of the Advancer – with “J” retracted – into the hole in the rear of the Arrow Raulerson Syringe plunger (refer to Fig. 5).




Fig. 5

- Advance spring-wire guide into the syringe approximately 10 cm until it passes through the syringe valves (refer to Fig. 6).




Fig. 6

- Raise your thumb and pull the Advancer approximately 4 cm to 8 cm away from the syringe. Lower thumb onto the Advancer and while maintaining a firm grip on the spring-wire guide, push the assembly into the syringe barrel to further advance the spring-wire guide. Continue until spring-wire guide reaches desired depth (refer to Fig. 7).




Fig. 7

Alternate Technique:

If a simple straightening tube is preferred, the straightening tube portion of the Advancer can be disconnected from the unit and used separately.

Separate the Advancer tip or straightening tube from the blue Advancer unit. If the “J” tip portion of the spring-wire guide is used, prepare for insertion by sliding the plastic tube over the “J” to straighten. The spring-wire guide should then be advanced in the routine fashion to the desired depth.

- When using an Arrow Raulerson Syringe, advance guide wire until triple band mark reaches rear of syringe plunger. Advancement of “J” tip may require a gentle rotating motion. **Warning: Do not cut spring-wire guide to alter length. Do not withdraw spring-wire guide against needle bevel to minimize the risk of possible severing or damaging of spring-wire guide.**
- Hold spring-wire guide in place and remove introducer needle and Arrow Raulerson Syringe (or catheter). **Precaution: Maintain firm grip on spring-wire guide at all times.** Use centimeter markings on spring-wire guide to adjust indwelling length according to desired depth of indwelling catheter placement.
- Enlarge cutaneous puncture site with cutting edge of scalpel positioned away from the spring-wire guide. **Precaution: Do not cut guide wire.** Use dilator to enlarge site as required. **Warning: Do not leave dilator in place as an indwelling catheter to minimize the risk of possible vessel wall perforation.**
- Thread tip of two-lumen catheter over spring-wire guide. Sufficient guide wire length must remain exposed at hub end of catheter to maintain a firm grip on guide wire. Grasping near skin, advance catheter into vein with slight twisting motion.

12. Using centimeter marks on catheter as positioning reference points, advance catheter to final indwelling position. All centimeter marks are referenced from the catheter tip. Marking symbology is as follows: (1) numerical: 5, 15, 25, etc.; (2) bands: each band denotes 10 cm intervals, with one band indicating 10 cm, two bands indicating 20 cm, etc.; (3) each dot denotes a 1 cm interval. When using a subclavian approach, the catheter can be oriented with the outflow (arterial) sideholes toward the center of the vessel to reduce the possibility of contact between the outflow sideholes and the vessel wall.
13. Hold catheter at desired depth and remove spring-wire guide. The Arrow catheter included in this product has been designed to freely pass over the spring-wire guide. If resistance is encountered when attempting to remove the spring-wire guide after catheter placement, the spring-wire may be kinked about the tip of the catheter within the vessel (refer to Fig. 8).




Fig. 8

- In this circumstance, pulling back on the spring-wire guide may result in undue force being applied resulting in spring-wire guide breakage. If resistance is encountered, withdraw the catheter relative to the spring-wire guide about 2-3 cm and attempt to remove the spring-wire guide. If resistance is again encountered, remove the spring-wire guide and catheter simultaneously. **Warning: Although the incidence of spring-wire guide failure is extremely low, practitioner should be aware of the potential for breakage if undue force is applied to the wire.**
14. Verify that the entire spring-wire guide is intact upon removal.
 15. Check lumen placement by attaching a syringe to each extension line and aspirate until free flow of venous blood is observed. Connect both extension lines to appropriate Luer-Lock line(s) as required. Unused port(s) may be "locked" through injection cap(s) using standard hospital protocol. Pinch clamps are provided on extension lines to occlude flow through each lumen during line and injection cap changes. **Precaution: To minimize the risk of damage to extension lines from excessive pressure, each clamp must be opened prior to infusing through that lumen.**
 16. Secure and dress catheter temporarily.
 17. Verify catheter tip position by chest x-ray immediately after placement. **Precaution: X-ray exam must show the catheter located in the right side of the mediastinum in the SVC with the distal end of the catheter parallel to the vena cava wall and its distal tip positioned at a level above either the azygos vein or the carina of the trachea, whichever is better visualized.** If catheter tip is malpositioned, reposition and re-verify.
 18. Secure catheter to patient. Use triangular juncture hub with integral rotating suture wings as primary suture site. **Precaution: Do not suture directly to the outside diameter of the catheter or impeding catheter flow.**

19. The removable suture wing, where provided, may be used as a secondary suture site.
 - Place fingers on the suture wings and apply pressure until the hub splits open.
 - Position suture wing around the catheter body adjacent to the venipuncture site.
 - Secure wings in place to patient, using suturing technique per hospital protocol.
 - **Warning: When using a curved catheter, do not insert any portion of the curved catheter body into the vein to minimize risk of catheter complication.**
20. When using a You-Bend Catheter, the extensions of You-Bend catheter may be formed to a desired shape or location. **Precaution: The extension lines of You-Bend are not to be re-formed on a continuous basis. Excessive re-forming of the extensions may lead to wire fatigue and breakage.**
21. Dress puncture site per hospital protocol. **Precaution: Maintain the insertion site with regular meticulous redressing using aseptic technique.**
22. Record on the patient's chart the indwelling catheter length as to centimeter markings on catheter where it enters the skin. Frequent visual reassessment should be made to ensure that the catheter has not moved.

Catheter Exchange Procedure:

Use sterile technique.

1. Proceed per hospital protocol. Cutting the catheter is not recommended due to the potential for catheter embolism.
2. When using a You-Bend Catheter, straighten extension line(s) prior to passing spring-wire guide.

Catheter Removal Procedure:

1. **Precaution: Place the patient in a supine position.**
2. Remove dressing. **Precaution: To minimize the risk of cutting the catheter do not use scissors to remove the dressing.**
3. **Warning: Exposure of the central vein to atmospheric pressure may result in entry of air into the central venous system.** Remove suture(s) from primary suture site. Be careful not to cut the catheter. Remove catheter slowly, pulling it parallel to the skin. As catheter exits the site, apply pressure with a dressing impermeable to air. Because the residual catheter track remains an air entry point until completely sealed, the occlusive dressing should remain in place for at least 24-72 hours dependent upon the amount of time the catheter was indwelling.^{17,27,29,33}
4. Upon removal of the catheter, inspect it to make sure that the entire length has been withdrawn.
5. Document removal procedure.

Heparinization (Hemodialysis):

1. A variety of "locking" solution concentrations are utilized to maintain the patency of the catheter. The amount of heparin used depends on physician preference, hospital protocol, and patient condition.²⁸
2. The volume of heparin solution should be equal to or slightly more than the volume of the lumen that is being "locked".
3. **Warning: Prior to hemodialysis, the indwelling heparin must be aspirated from each lumen. After the heparin has been aspirated the lumens should be flushed with sterile normal saline solution.**

Poor Blood Flow:

1. If there is difficulty maintaining adequate blood flow during the hemodialysis treatment, the following measures can be tried: lower patient's head, change patient's position, apply external pressure to catheter exit site over sterile dressing, check for catheter kinks, rotate catheter if moveable within rotating suture wings, loosen tight dressing, reverse blood flow only if other attempts fail.²⁰
2. If the above measures fail and the flow problems are felt to be due to a clotted catheter, fibrinolytic agents can be used as prescribed.














References:

1. Bar-Joseph G, Galvis AG. Perforation of the heart by central venous catheters in infants: guidelines to diagnosis and management. *J Pediatr Surg.* 1983;18:284-287.
2. Bambauer R, Inniger R, Pirrung KJ, Schiel R, Dahlem. Complications and side effects associated with large-bore catheters in the subclavian and internal jugular veins. *Artificial Organs.* 1994;18:318-321.
3. Blitt CD, ed. *Monitoring in Anesthesia and Critical Care Medicine.* Central venous pressure monitoring. New York, NY: Churchill Livingstone; 1985:121-165.
4. Brandt RL, Foley WJ, Fink GH, Regan WJ. Mechanism of perforation of the heart with production of hydropericardium by a venous catheter and its prevention. *Am J Surg.* 1970;119:311-316.
5. Carbone K, Gimenez LF, Rogers WH, Watson AJ. Hemothorax due to vena caval erosion by a subclavian dual-lumen dialysis catheter. *South Med J.* 1987;80:795-796.
6. Collier PE, Ryan JJ, Diamond DL. Cardiac tamponade from central venous catheters – report of a case and review of the English literature. *Angiology.* September 1984;35:595-600.
7. Collin GR. Decreasing Catheter Colonization Through the Use of an Antiseptic-Impregnated Catheter. *Chest* June 1999;115:1632-1640.
8. Conn C. The importance of syringe size when using implanted vascular access devices. *J Vasc Access Nurs.* Winter 1993;3:11-18.
9. Curelaru J, Linder LE, Gustavsson B. Displacement of catheters inserted through internal jugular veins with neck flexion and extension. *Intens Care Med.* 1980;6:179-183.
10. Eissa NT, Kvetan V. Guide wire as a cause of complete heart block in patients with preexisting left bundle branch block. *Anesthesiology.* 1990;73:772-774.
11. Farber T. ARROWgard™ antiseptic surface toxicology review. Monograph. Published by Arrow International, Inc. April, 1992.
12. Fukui A, Ohsumi A, Takaori M. A case of anaphylactic shock induced by chlorhexidine gluconate. *J Japan Society Clin Anesthesia.* 1989;9:356-360.
13. Greenfeld JJ, Sampath L, Popilskis SJ, et al. Decreased Bacterial Adherence and biofilm formation on chlorhexidine and silver sulfadiazine-impregnated central venous catheters implanted in swine. *Crit Care Med.* 1995;23:894-900.
14. Harukuni I, Ishizawa Y, Nishikawa T, Takeshima R, Dohi S, Naito H. Anaphylactic shock with ventricular fibrillation induced by chlorhexidine. *Japanese J Anesthesiology.* 1992;41:455-459.
15. Iberti TJ, Katz LB, Reiner MA, Brownie T, Kwun KB. Hydrothorax as a late complication of central venous indwelling catheters. *Surgery.* November 1983;842-846.
16. Jobs DR, Schwartz AJ, Greenhow DE, Stephenson LW, Ellison N. Safer jugular vein cannulation: recognition of arterial punctures and preferential use of the external jugular route. *Anesthesiology.* 1983;59:353-355.
17. Kashuk JL, Penn I. Air embolism after central venous catheterization. *Surg Gynecol Obstet.* September 1984;159:249-252.
18. Kozeny GA, Bansal VK, Vertuno LL, Hano JE. Contralateral hemothorax secondary to chronic subclavian dialysis catheter. *Am J Nephrol.* 1984;4:312-314.
19. Kubo H, Akiyama Y, Honda K, Nakajo N. Anaphylaxis following oral irrigation with chlorhexidine gluconate. *J Japanese Dental Society Anesthesiology.* 1985;13:659-663.
20. Lancaster LE, ed. *ANNA Core Curriculum for Nephrology Nursing.* 2nd ed. Pitman, NJ: Anthony J. Jannetti, Inc.; 1990:270-271.
21. Layton GT, Stanworth DR, Amos HE. The incidence of IgE and IgG antibodies to chlorhexidine. *Clin Experimental Allergy.* 1989;19:307-314.
22. Maki DG, Wheeler SJ, Stolz SM, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter. *Ann Int Med.* August 15, 1997;127:257-266.
23. Maschke SP, Rogove HJ. Cardiac tamponade associated with a multilumen central venous catheter. *Crit Care Med.* 1984;12:611-612.
24. Modak SM. (Written communication, June 1991).
25. Okano M, Nomura, Hata S, et al. Anaphylactic symptoms due to chlorhexidine gluconate. *Arch Dermatol.* 1989;125:50-52.
26. Okano M, Nomura M, Okada N, Sato K, Tashiro M. Four cases presenting anaphylactic reactions due to topical application of Hibitane®. *Skin Research.* 1983;25:587-592.
27. Paskin DL, Hoffman WS, Tuddenham WJ. A new complication of subclavian vein catheterization. *Ann Surg.* March 1974;179:266-268.
28. Peters JL, ed. *A Manual of Central Venous Catheterization and Parenteral Nutrition.* Boston, MA: John Wright PSG; 1983:58-61, 155-157.
29. Phifer TJ, Bridges M, Conrad SA. The residual central venous catheter track – an occult source of lethal air embolism: case report. *J Trauma.* 1991;31:1558-1560.
30. Sheep RE, Guiney WB Jr. Fatal cardiac tamponade. *JAMA.* 1982;248:1632-1635.
31. Sigurdsson J, Riba P, Sigurdsson S. The wandering central venous catheter. *Intensive Care Med.* 1985;11:263-264.
32. Takeda K, Inoue K, Matsuya T, et al. An allergic shock possibly induced by the chlorhexidine; report of a case. *J Osaka Univ Dent Soc.* 1985;30:221-225.
33. Thielen JB, Nyquist J. Subclavian catheter removal. *J Intravenous Nurs.* March/April 1991;14:114-118.
34. Tocino IM, Watanabe A. Impending catheter perforation of superior vena cava: radiographic recognition. *Am J Roentgenology.* March 1986;146:487-490.
35. Tsuneto S, Watanabe S, Koyama K, Nakayama K, Saito H, Saito K. Anaphylactic shock induced by chlorhexidine mixed

- in the vial of lidocaine. *J Japan Society Clin Anesthesia*. 1987;7:272-277.
36. Vaziri ND, Maksy M, Lewis M, Martin D, Edwards K. Massive mediastinal hematoma caused by a double-lumen subclavian catheter. *Artif Organs*. 1984;8:223-226.
 37. Veenstra DL, Saint S, Saha S, et al. Efficacy of Antiseptic – impregnated central venous catheters in preventing catheter-related bloodstream infection, A meta – analysis. *JAMA*. 1999;281:261-267.
 38. Wanscher M, Frifelt JJ, Smith-Sivertsen C, et al. Thrombosis caused by polyurethane double-lumen subclavian superior vena cava catheter and hemodialysis. *Crit Care Med*. 1988;16:624-628.
 39. Data on file, Arrow International, Inc.
 40. Acute Dialysis Catheters; Oliver MJ; *Semin Dial*. 2001 Nov-Dec; 14(6):432-5.
 41. Central Vein Stenosis: a Nephrologists' Perspective; Agarwal AK, Patel BM, Jaddad NJ; *Semin Dial* 2007 Jan-Feb 20:1:53-62.
 42. Post Catheterization vein Stenosis in Hemodialysis: Comparative Angiographic Study of 50 Subclavian and 50 Internal Jugular Accesses; Schillinger, F et al. *Nephrol Dial Transplant* 1991; 6:722-724.
 43. Thrombosis and Stenosis of Central Venous Access in Hemodialysis: Vanherweghem, JL. *Nephrologie* 1994;15 (2):117-121.
 44. National Kidney Foundation KDOQI Guidelines. Clinical Practice Guidelines and Clinical Practice Recommendations; Update 2006.
- Arrow International, Inc. recommends that the user be acquainted with the reference literature.
- *If you have any questions or would like additional reference information, please contact Arrow International, Inc.

Rx only.

Symbol Glossary

								
Caution	Consult instructions for use	Do not reuse	Do not resterilize	Sterilized by ethylene oxide	Keep away from sunlight	Keep dry	Do not use if package is damaged	Not made with natural rubber latex
								
Catalogue number	Lot number	Use by	Manufacturer					

K-22142-103A (5/15)

ARROW[®]

INTERNATIONAL

2400 Bernville Road
Reading, PA 19605 USA
1-800-523-8446 | 1-610-378-0131